Serum estrone concentration, estrone sulfate/estrone ratio and BMI are associated with human epidermal growth factor receptor 2 and progesterone receptor status in postmenopausal primary breast cancer patients suffering invasive ductal carcinoma

Borbála Vincze1*, Bence Kapuvári1, Nóra Udvarhelyi2, Zsolt Horváth3, Zoltán Mátrai4, Ferenc Czeyda-Pommersheim4, Krisztina Köhalmy1, Judit Kovács1, Mariann Boldizsár1, István Láng5 and Miklós Kásler6

Abstract

Background: We investigated in postmenopausal women with primary breast cancer prior to surgical intervention whether, serum levels of different steroid hormones and hormonal precursors associated with tumor tissue estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status.

Methods: We enrolled 1,042 patients suffering invasive ductal carcinoma undergoing surgical resection in the National Institute of Oncology, Hungary between 2003 and 2011. Serum parameters were measured by RIA/IRMA assays; tumor tissue ER, PR and HER2 status was assessed histologically. Patients were classified according to tumor receptor status. Case–case analysis subjects were categorized into four subgroups based on serum hormone concentrations in ER, PR and HER2 receptor-negative cases, respectively.

Results: Serum estrone sulfate and dehydroepiandrosterone sulfate levels correlated with each other and also with serum estrone and estradiol levels. According to case–case study the odds ratios in the highest quartile were 1.517 (p = 0.0305, P_trend = 0.0394) for androstenedione, 1.495 (p = 0.0317, P_trend < 0.0105) for estrone and 0.654 (p = 0.0273, P_trend < 0.0151) for estrone sulfate/estrone ratio in PR+ vs. PR− tumors. Regarding HER2 status (HER2+ vs. HER2−), the odds ratios for estrone, estrone sulfate and estrone sulfate/estrone ratio were 0.530 (p = 0.0234, P_trend = 0.0595), 2.438 (p = 0.0042, P_trend < 0.0066) and 3.118 (p = 0.0001, P_trend < 0.0001) in the highest quartile, respectively. Of note significantly increased BMI associates with PR+ and ER+/PR+ status while significantly decreased BMI was observed in HER2+ cases.

Conclusions: Taken together, measurement of serum estrone and estrone sulfate concentrations prior to surgical intervention might support the individualization of regime in postmenopausal primary breast cancer patients.

Keywords: Postmenopausal breast cancer, Invasive ductal carcinoma, Estrone, Estrone sulfate, Progesterone receptor, HER2

*Correspondence: vincze@oncol.hu
1 Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9, Hungary
Full list of author information is available at the end of the article

© 2015 Vincze et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Background
Breast cancer is a very heterogeneous disease that can be classified to molecular, histopathologic and clinical subgroups. Anticancer therapy is determined by biological characteristics and stage of the tumor. Most important biological features determining therapy are endocrine sensitivity, human epidermal growth factor receptor 2 (HER2) expression and proliferative capability of the tumor (Láng et al. 2012).

Approximately 70% of breast cancer cases express estrogen receptor (ER) and progesterone receptor (PR) thus are referred as hormone receptor (HR)-positive. HER2 expression is presented in 20–25% of breast cancer cases that are classified as HER2-positive (HER2+) (Ross et al. 2009; Dawood et al. 2010). Approximately 50% of HER2-positive cases are also HR-positive (ER+/PR+/HER2+) (Dowsett et al. 2008; Tripathy et al. 2013; Mehta and Tripathy 2014). About 10–20% of invasive breast cancer cases do not express ER, or HER2 and are termed as of triple negative receptor status (ER−/PR−/HER2−) (Perou 2011; Aysola et al. 2013).

Estrogens play a crucial role in breast cancer progression through inhibition of apoptosis and stimulation of cell proliferation via ER activation (Hankinson and Eliasm 2007). Several epidemiological studies indicate that plasma estradiol (E2), adrenal androgens and testosterone (TE) levels were higher in women who developed ER-positive breast cancer later (Key et al. 2002; Zeleniuch-Jacquotte et al. 2004; Misser et al. 2004; Kaaks et al. 2005; Cummings et al. 2005; Sieri et al. 2009; Endogenous Hormones and Breast Cancer Collaborative Group 2013).

A Danish population-based prospective study revealed that the association between the risk of postmenopausal breast cancer and serum estrone (E1) or estrone sulfate (E1S) levels is stronger than that between E2 and breast cancer risk (Würtz et al. 2012). Zhang et al. (2013) demonstrated that blood sex hormone levels measured at a single time-point would predict the development of breast cancer within up 16–20 years.

Epidemiological studies focused on the association between sex hormones and breast cancers or excluded ER-negative breast cancers from the analysis (Key et al. 2002; Zeleniuch-Jacquotte et al. 2004; Kaaks et al. 2005; Cummings et al. 2005). The reason of exclusions from several cohort studies is that the number of ER−/PR−cases was relatively small; the statistical power was insufficient to assess other relevant breast cancer subtypes, such as triple negative, or HER2-positive (Zhang et al. 2013).

It is well documented that ER/PR and HER2 status predict the clinical outcome and the response to adjuvant endocrine therapy or poly-chemotherapy. However, a detailed hormone profile determined before surgical intervention can also support to predict the hormone sensitivity of the tumor. Based on biological and clinical observations it was suggested that plasma levels of sulfoconjugated and unconjugated steroid hormones and tissue-specific expression of steroid sulfatase (STS) might play a significant role in breast cancer biology and might regulate the effects of endocrine therapy (Falany and Falany 2007). Kim et al. found that high preoperative serum E2 level indicate worse prognosis in postmenopausal women with breast cancer, particularly in those with ER-negative cancer (Kim et al. 2013). However, the interaction between sexual hormone levels before surgery and receptor status was not investigated widely.

Our aim was to investigate whether circulating steroid hormone levels including sexual hormones and their precursors along with sex hormone binding globulin [i.e. E1, E1S, E2, TE, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEAS), androstenedione (AD) and SHBG] measured prior surgical intervention show any association with tumor ER, PR and HER2 status in postmenopausal women with primary breast cancer. In our case–case study the relationship between serum sexual hormone levels and tumor ER, PR and HER2 status was retrospectively studied using data collected from postmenopausal patients treated with breast cancer between 2003 and 2011 in the National Institute of Oncology, Hungary.

Methods
Patients
Our study involved 1381 postmenopausal patients with primary breast cancer (stages ranging between 0 and III). Women were considered postmenopausal when they reported not having any menstrual cycles in the past 24 months; those with bilateral ovariectomy in medical history; and those with age above 55 years (Kaaks et al. 2005).

Distribution of the patients according to age: 485 cases (55–59 years), 528 cases (60–69 years), 271 cases (70–79 years) and 97 cases (≥80 years). The mean age of the population studied was 64.7 ± 9.1 years.

The diagnosis of breast cancer was confirmed by histology in all cases. Tumors had been diagnosed by experienced pathologists using standard criteria for histology and grading. All patients had resectable stage 0–III tumors according to the TNM 6.0 staging (Union International Cancer Congress, TisNOM0–T2N3M0).

The histological diagnosis was mainly invasive ductal carcinoma (IDC) 1,042 (75.45%), IDC in situ (DCIS) 84 (6.08%), invasive lobular carcinoma (ILC) 140 (10.14%) and others 115 (8.33%) (including metaplastic, adenoid, papillary, apocrine, cribriform, medullary, mucinous and...
tubular invasive carcinomas). Patients were diagnosed mainly with IDC (1,042 cases) therefore statistical analysis was performed within this subgroup.

The study was approved by the Institutional Review Board and Ethics Committee of National Institute of Oncology, Hungary since 2003. Permission of the Hungarian Regional Committee of Science and Research Ethics was obtained for retrospective evaluation of the data (Number of permission: 322/2014).

At the time of blood sampling all patients was informed about the purpose of our study. Written informed consent was obtained from all individual participants included in the study. Patients donated 8–10 ml blood sample and completed a questionnaire about reproductive history, previous use of contraceptives, postmenopausal hormone replacement therapy (HRT). Women who used HRT at the last 6 months and/or had a diagnosis of cancer within 10 years before surgical intervention were not elected to the present study. Patients who received neoadjuvant chemotherapy were excluded, as well.

Determination of serum hormone levels
Blood samples were collected according to a standardized protocol. Briefly, the whole blood was centrifuged at 2,500 g for 15 min. The serum was removed from the blood clot and stored in aliquots at −20°C until the determination. Measurements were carried out within 2–3 months in all cases. Steroid hormone assays were performed in our Laboratory on Department of Biochemistry (NIO). Since the concentration of serum E2 is usually lower than 40 pmol l$^{-1}$ in postmenopausal women, serum E2 level was determined by using an ultra-sensitive estradiol radioimmunoassay (RIA) kit (Immunotech, Prague, Czech Republic, detection limit: 8.14 pmol l$^{-1}$). E1S, DHEA and AD were measured by RIA kit (Immunotech, Prague, Czech Republic). Total TE and DHEAS were measured by Immunotech SAS RIA kit (Marseille, France); E1 concentration was measured by RIA with a DiaSource Immunoassays S.A. kit (Louvain-la-Neuve, Belgium). SHBG was measured by Izinta kit (Isotope Institute, Budapest, Hungary). The mean intra- and inter-assay coefficient of variations were 7.5 and 9.4% for E2, 14.8 and 15.0% for TE, 6.3 and 8.6% for E1, 6.1 and 4.3% for SHBG, 9.2 and 8.8% for E1S, 5.6 and 9.8% for AD, 7.4 and 10.6% for DHEAS, 3.8 and 8.6% for DHEA. Stratex CR 300 (Birkenfeld, Germany) an automatic open analyser system was used to detect $^{125}$I radioactivity.

Free TE and E2 concentrations were calculated from the concentrations of E2, TE and SHBG according to previous studies (Vermeulen et al. 1999; Endogenous Hormones and Breast Cancer Collaborative Group 2003).

Assessment of tumor receptor status
The ER and PR status were evaluated histologically on immunohistochemical (IHC) slides [ER: SP1 (NeoMarkers), PR: NCL-L. PGR-312 (Novocastra)]. ER and PR positivity were defined when at least 10% prevalence of malignant cells exhibiting staining characteristics.

HER2 protein overexpression was assessed by IHC method using three different antibodies: RTV-CB11 (Novocastra), C-erbB-2/Her-2/neu SP3 clone (NeoMarkers) and HercepTest (DAKO). Samples were scored using the recommended scoring system for the HercepTest.

HER2 gene amplification was tested with the InformHER2 test by Ventana. The updated cut-off value for positive cases is more than six copies of the gene. HER2 was scored positive if the result was 3+; 2+ was considered to be positive only if it was confirmed by fluorescence in situ hybridization (FISH).

Statistical analysis
MedCalc Software was used for statistical analysis. In the case of a normal distribution, the correlation between serum hormone parameters was calculated using the correlation coefficient (r), in the remaining cases Spearman’s coefficient of rank correlation (rho) was used. 95% confidence interval (95% CI) for r or rho was computed.

During case–case study hormone receptor-positive vs. hormone receptor-negative postmenopausal breast cancer patients by quartiles of serum steroid concentration were compared. The hormone receptor negative cases were categorized into four classes according to hormone levels. Receptor-positive/receptor-negative ratio was calculated belong to the four serum hormone concentration ranges. Odds ratios (ORs) were computed taking the lowest category of hormone receptor-negative cases as reference (Begg and Zhang 1994). ORs with 95% CIs and $P_{trend}$ are presented by quartile limits of serum parameters.

Chi-square test was used (with Yates’ correction for continuity) for the investigation of independence of numerical variables and the determination of linear trends ($P_{trend}$) among the groups classified by tumor receptor status.

Results
Selection of case subjects
IDC patients (1,042 cases) were categorized according to histological grade (HG), stadium (St) and ER, PR, HER2 receptor status (Table 1).

We classified the cases according to their joint status of hormone and HER2 receptors. For the case–case study we defined the following tumor subtypes: ER+ (852 cases) vs. ER− (190 cases); PR+ (709 cases) vs. PR− (333 cases); ER+/PR+ (703 cases) vs. ER−/PR− (184 cases); ER+/PR− (149 cases) vs. ER−/PR− (184 cases) and
HER2+ (123 cases) vs. HER2− (949 cases) (Table 1). In addition, further subgroups were also established according to the combined presence/absence of ER, PR and HER2. These subgroups were as follows: HER2+/ER+/PR+ (33 cases) vs. HER2−/ER+/PR+ (670 cases); HER2+/ER−/PR− (65 cases) vs. HER2−/ER−/PR− (119 cases) and HER2−/ER+/PR+ (670 cases) vs. HER2−/ER+/PR− (125 cases) (Table 1).

**Table 1 Categorization of the subjected primary breast cancer patients suffering invasive ductal carcinoma (IDC) (total number: 1,042) according to histological grade (HG), stadium (St) and receptor status**

| Factor | Number |
|--------|--------|
| **IDC histological grade (HG) (IDC total number: 1,042)** | |
| HG 1 | 244 |
| HG 2 | 425 |
| HG 3 | 373 |
| **IDC stadium (St) (IDC total number: 1,042)** | |
| 1 | 489 |
| 2 | 336 |
| 2a | 103 |
| 2b | 43 |
| 3 | 47 |
| 3a | 15 |
| 3b | 2 |
| 3c | 7 |
| **Receptor status (IDC total number: 1,042)** | |
| ER+ | 852 |
| ER− | 190 |
| PR+ | 709 |
| PR− | 333 |
| ER+/PR+ | 703 |
| ER−/PR− | 184 |
| ER+/PR− | 149 |
| ER−/PR+ | 6 |
| HER2+ | 123 |
| HER2− | 949 |
| HER2+/ER+/PR+ | 33 |
| HER2−/ER+/PR+ | 670 |
| HER2+/ER−/PR− | 125 |
| HER2−/ER−/PR− | 65 |
| HER2+/ER+/PR− | 119 |

**HER2** estrogen receptor, **PR** progesterone receptor, **HER2** human epidermal growth factor receptor 2.

**Serum hormone levels**

Hormone measurements were completed for all 1,042 cases except E2. Until 2005, the IMMUNOTECH RIA kit had been used for serum E2 measurements, which had low sensitivity in the range of <40 pmol L−1. The values of E2 concentration measured by the two different kits significantly differ from each other. Therefore, the measurements done with IMMUNOTECH RIA kit were excluded from the analysis (392 subjects).

Later on the serum E2 concentration was measured with an ultra-sensitive RIA kit in 650 (62%) patients. The average E2 value was 60.53 pmol L−1 (95% CI of the mean was 54.97–66.09), therefore this ultra-sensitive kit is appropriate for the detection of low serum E2 level in the majority of postmenopausal women. Only these data were used in the statistical analysis.

Serum concentrations of the steroid hormones correlated significantly with each other. DHEAS significantly correlated with DHEA r = 0.704 (p < 0.0001), TE/SHBG ratio r = 0.441 (p < 0.0001) and AD rho = 0.391 (p < 0.0001) (data are not shown). Serum E1 and E2 levels strongly correlated with DHEAS (r = 0.543, p < 0.0001 and r = 0.463, p < 0.0001) (data are not shown) and with E1S, the major substrate for STS (r = 0.457, p < 0.0001 and r = 0.509, p < 0.0001), respectively (Fig. 1a, b). E1 and E2 correlated significantly with each other r = 0.518 (p < 0.0001) and with androgens (AD, free TE) (data are not shown). The association between E1 and AD, as well as E2 and TE/SHBG, was r = 0.415 (p < 0.0001) and r = 0.433 (p < 0.0001), respectively (data are not shown). The serum levels of sulfoconjugated steroids (DHEAS, E1S) also correlated significantly with each other r = 0.529 (p < 0.0001) (Fig. 2).

**Case–case study**

To assess the impact of receptor status on serum steroid hormone levels, case–case comparisons and Chi-square test were used (OR, 95% CI, Ptrend). IDC patients (1,042 cases) were categorized into different classes based on hormone receptor status as written earlier.

In ER+ vs. ER− tumors the alteration of ORs were significant only in case of E1 level (OR = 1.663, p = 0.0026, P trend = 0.0101) (Table 2).

Our results showed that E1 levels were significantly elevated in the fourth quartile of PR+ vs. PR− tumors (OR = 1.495, p = 0.0317; P trend = 0.0105). The same association was observed in case of serum AD levels (OR = 1.517, p = 0.0305; P trend = 0.0394). Due to association between E1S and E1 levels we examined the association between E1S/E1 ratio and hormone receptor status (PR+ vs. PR−). E1S/E1 ratio significantly decreased (OR = 0.654, p = 0.0273) and a significant trend was also present (P trend = 0.0151). There was no significant difference in serum E2, TE SHBG concentrations and E2/SHBG ratio. The TE/SHBG ratio showed only a significant trend (P trend = 0.022). In case of BMI, we found a significant elevation in the third (OR = 1.638,
positive trend ($P_{\text{trend}} = 0.0066$) in the fourth (OR = 2.438, $p = 0.0042$) quartiles in HER2-positive cases. The ratio of E1S/E1 was increased significantly (OR = 3.118, $p = 0.0001$) with a positive trend ($P_{\text{trend}} < 0.0001$). In addition, AD/E1 ratio also showed significant elevation (OR = 1.922, $p = 0.0282$) in the third quartile, but the trend was not seen. BMI significantly decreased in the fourth quartile (OR = 0.475, $p = 0.0113$) and the trend was also significant ($P_{\text{trend}} = 0.0027$) (Fig. 4).

Contrary to ER+ vs. ER− and ER+/PR+ vs. ER−/PR− subgroups in HER2−/ER+ vs. HER2−/ER− cases serum E2, E2/SHBG and E1S/E1 ratios showed significant or nearly significant trend. OR of E2 (OR = 1.667) and E2/SHBG (OR = 1.992) increased in the fourth quartile; with positive trend ($P_{\text{trend}} = 0.0544$, $P_{\text{trend}} = 0.0257$). Similar to PR+ vs. PR− cases, OR of E1S/E1 decreased to 0.582 in the fourth quartile and the trend was nearly significant ($P_{\text{trend}} = 0.0530$). OR of BMI increased in the fourth quartile (OR = 1.887) with a nearly significant trend ($P_{\text{trend}} = 0.0538$) (Table 2).

HER2+/ER−/PR− vs. HER2−/ER−/PR− cases did not show any significant changes. Interestingly, E1S/E1 ratio elevated in the fourth quartile (OR = 2.083) with an almost significant positive trend ($P_{\text{trend}} = 0.0724$) (Table 2). In addition, AD/E1 (OR = 2.750, $p = 0.0387$) and TE/SHBG (OR = 2.667, $p = 0.0363$) ratios showed significant elevation in the second quartile.

Taking account of hormone receptor (HR) status next to HER2 positivity we found the greatest variances in the
Table 2 Case–case comparison of receptor-positive vs. receptor-negative postmenopausal IDC breast cancer patients by quartiles of serum steroid concentrations

| Receptor status | Case–case study, odds ratio |
|-----------------|---------------------------|
|                 | E2 (pmol l⁻¹) | E2/SHBG | E1 (pmol l⁻¹) | E1S (pmol l⁻¹) | E1S/E1 | AD (nmol l⁻¹) | TE (nmol l⁻¹) | TE/SHBG | BMI (kg/m²) |
| (ER+)/ (ER−)    | 0.82           | 1.09  | 1.66**    | 1.26           | 0.72  | 1.24           | 1.50          | 1.20      | 1.12       |
| (PR+)/ (PR−)    | 1.09           | 1.36  | 1.5*      | 1.08           | 0.65* | 1.52*          | 1.36          | 1.39      | 1.66*      |
| (ER+/PR+)/ (ER−/PR−) | 0.84   | 1.18  | 1.77*     | 1.23           | 0.66  | 1.31           | 1.56          | 1.29      | 1.70*      |
| (HER2+/HER−)    | 1.32           | 1.99  | 0.53*     | 2.44**         | 3.12*** | 0.81         | 0.99          | 1.04      | 0.48*      |
| (HER2+/PR−)/(HER−/PR−) | 0.25  | 1.00  | 0.56      | 1.08           | 2.08  | 0.71           | 1.13          | 1.33      | 0.46       |
| (HER2−/HER+/PR−) | 1.67           | 1.99  | 1.38      | 1.07           | 0.58  | 1.51           | 1.11          | 1.43      | 1.89       |
| (HER2+/PR−)/(HER−/PR−) | 2.00  | 9.00* | 1.50      | 17.00**        | 6.00* | 2.14          | 11.60*        | 2.25      | 0.42       |
| (HER2+/PR−)/(HER−/PR−) | 6.94           | 7.00  | 0.83      | 17.00*         | 31.19* | 1.22         | 1.66          | 2.25      | nd         |

Odds ratios in the fourth quartile are shown. Rows in italics present comparisons where number of cases is small therefore these results are only informative. Further investigations are needed.

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, E1 estrone, E1S estrone sulfate, E2 estradiol, TE testosterone, AD androstenedione, SHBG sex hormone binding globulin, BMI body mass index, OR odds ratio, nd no data.

Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.

Discussion

The strength of our study compared with previous reports is the large number of IDC cases (1,042 patients) which enables us to evaluate the association between serum parameters and receptor status not only in HR-positive, but HER2-positive and HR-negative cases.

In our study the serum level of steroid hormones, hormone-precursors and SHBG were measured prior to surgical intervention in postmenopausal women with primary breast cancer. The associations between E1 and E1S and between E2 and E1S and between DHEAS and E1 indicate the importance of circulating E1S and DHEAS as peripheral estrogen pools in serum (Labrie 2015).

After menopause, E2 plasma level decreases by 90% (Russo and Russo 2006) and the primary estrogen is E1. Others have already reported that serum E2 level is not a reliable risk predictor for postmenopausal women. This may be due to methodological issues as E2 levels are generally around the level of detection in menopause; therefore, E1 levels are preferred (Miyoshi et al. 2003a).

In patients with diagnosed breast cancer our results for E2, E1 and E1S are consistent with literary data (Miyoshi et al. 2003a). In patients with diagnosed breast cancer our results for E2, E1 and E1S are consistent with literary data (Würtz et al. 2012). Based on our case–case studies the serum E1 concentration and E1S/E1 ratio associated tumor HR and HER2 status. Of note, high E1 level and low E1S/E1 ratio associate with HR-positivity, particularly PR+ and ER+/ PR+ cases. Regarding HER2, decreased E1 level and elevated E1S/E1 ratio were measured in HER2-positive cases.

Our results also support the pivotal role of STS in peripheral cells (e.g. platelets and lymphocytes) (Bonser et al. 2000; Garrido et al. 2012) and tissues (i.e. normal breast and breast carcinoma cells). Presumably, serum E1S influences intratumoral estrogen biosynthesis through STS pathway. STS enzyme activity was detected in the great majority of breast carcinomas (Evans et al. 1994). In postmenopausal women the sulfatase pathway is more dominant then the aromatase route. The uptake and efflux of sulfoconjugated steroid hormones are mediated by transport proteins (Ugele et al. 2003). It was shown that organic anion transport protein 2B1...
**Fig. 3** Case–case comparison of progesterone receptor-positive (PR+) vs. progesterone receptor-negative (PR−) postmenopausal IDC breast cancer patients by quartiles of serum steroid concentration. Odds ratios (ORs) were computed taking the lowest category of hormone receptor-negative cases as reference. ORs with 95% CIs and \( P_{\text{trend}} \) are presented by quartile limits of serum parameters. Black squares show ORs in quartiles (Q1–Q4), and the horizontal lines show 95% CIs. ORs are shown on a log scale. Chi-square test was used for determination of linear trends (\( P_{\text{trend}} \)) among the groups classified by tumor receptor status. ER estrogen receptor, PR progesterone receptor, \( E_1 \) estrone, \( E_1S \) estrone sulfate, \( E_2 \) estradiol, TE testosterone, AD androstenedione, SHBG sex hormone binding globulin, BMI body mass index, OR odds ratio, CI confidence interval. Statistics: \( *p < 0.05 \).

| Hormone or protein | Quartile limits | OR 95% CI | \( P_{\text{trend}} \) |
|--------------------|----------------|----------|------------------|
| \( E_1 \) (pmol/l) |                |          |                  |
| Q01 <86.00         | 154/82        | 1.000 (referent) |          |
| Q02 66.00-118.59   | 137/83        | 0.879 (0.600 to 1.269) |          |
| Q03 119.00-166.90 | 180/83        | 1.155 (0.796 to 1.677) |          |
| Q04 >166.90        | 233/83        | 1.495* (1.036 to 2.157) | 0.0105   |

| \( E_1S \) (pmol/l) |                |          |                  |
| Q01 <2.056         | 186/82        | 1.000 (referent) |          |
| Q02 2.056-3.289    | 182/81        | 1.063 (0.745 to 1.574) |          |
| Q03 3.290-4.286    | 157/81        | 0.934 (0.640 to 1.364) |          |
| Q04 >4.286         | 179/80        | 1.070 (0.741 to 1.559) | 0.8924   |

| \( E_1S/E_1 \) |                |          |                  |
| Q01 <0.006591     | 211/80        | 1.000 (referent) |          |
| Q02 0.000961-0.00396 | 89/49        | 0.916 (0.562 to 1.497) |          |
| Q03 0.003947-0.001652 | 131/80       | 1.324 (0.904 to 1.926) |          |
| Q04 >0.001652     | 132/49        | 1.361 (0.946 to 2.003) | 0.0916   |

| \( E_2 \) (pmol/l) |                |          |                  |
| Q01 <37.10         | 101/50        | 1.000 (referent) |          |
| Q02 37.10-46.59    | 84/46         | 0.480 (0.263 to 0.889) |          |
| Q03 46.59-65.90    | 156/60        | 1.546 (0.970 to 2.549) |          |
| Q04 >65.90         | 119/50        | 1.059 (0.677 to 1.753) | 0.2502   |

**Calculated free \( E_2 \) (E2/SHBG) |**

|                |          |          |                  |
| Q01 <0.000591  | 97/49    | 1.000 (referent) |          |
| Q02 0.000991-0.00396 | 89/49    | 0.916 (0.562 to 1.497) |          |
| Q03 0.003947-0.001652 | 131/80  | 1.324 (0.904 to 1.926) |          |
| Q04 >0.001652  | 132/49   | 1.361 (0.946 to 2.003) | 0.0916   |

| \( TE \) (pmol/l) |                |          |                  |
| Q01 <1.180       | 150/82      | 1.000 (referent) |          |
| Q02 1.180-1.669  | 167/84      | 1.067 (0.746 to 1.563) |          |
| Q03 1.669-2.275  | 183/84      | 1.191 (0.830 to 1.739) |          |
| Q04 >2.275       | 207/69      | 1.363 (0.941 to 1.975) | 0.0950   |

**Calculated free \( TE \) (TE/SHBG) |**

|                |          |          |                  |
| Q01 <0.001908  | 158/63    | 1.000 (referent) |          |
| Q02 0.00185-0.001917 | 135/63 | 0.654 (0.281 to 1.501) |          |
| Q03 0.00316-0.003536 | 195/63 | 1.234 (0.653 to 2.360) |          |
| Q04 >0.00536   | 217/62    | 1.350 (0.963 to 2.000) | 0.0209   |

| \( SHBG \) (mg/l) |                |          |                  |
| Q01 <34.80       | 195/62     | 1.000 (referent) |          |
| Q02 34.80-49.39  | 169/63     | 0.896 (0.592 to 1.387) |          |
| Q03 49.40-71.69  | 163/63     | 0.927 (0.643 to 1.337) |          |
| Q04 >71.69       | 160/63     | 0.611 (0.400 to 1.000) | 0.3549   |

| \( AD \) (pmol/l) |                |          |                  |
| Q01 <2.7800       | 138/79      | 1.000 (referent) |          |
| Q02 2.7800-3.8796 | 173/82      | 1.206 (0.820 to 1.769) |          |
| Q03 3.8796-4.5269 | 172/62      | 1.201 (0.830 to 1.769) |          |
| Q04 >4.5269       | 212/60      | 1.517* (1.040 to 2.123) | 0.0305   |

| \( AD/E_1 \) |                |          |                  |
| Q01 <22.660       | 187/60     | 1.000 (referent) |          |
| Q02 22.660-33.509 | 197/61     | 1.040 (0.720 to 1.533) |          |
| Q03 33.510-47.899 | 149/60     | 0.740 (0.512 to 1.084) |          |
| Q04 >47.899       | 168/60     | 0.600 (0.418 to 0.860) | 0.2871   |

| BMI (kg/m²) |                |          |                  |
| Q01 <23.46       | 127/63     | 1.000 (referent) |          |
| Q02 23.46-26.66  | 164/63     | 1.291 (0.881 to 1.933) |          |
| Q03 26.67-30.29  | 208/63     | 1.630* (1.25 to 2.135) |          |
| Q04 >30.29       | 208/63     | 1.650* (1.39 to 2.140) | 0.0044   |
Fig. 4 Case–case comparison of HER2-positive vs. HER2-negative postmenopausal IDC breast cancer patients by quartiles of serum steroid concentrations. Odds ratios (ORs) were computed taking the lowest category of hormone receptor-negative cases as reference. ORs with 95% CIs and \( P_{\text{trend}} \) are presented by quartile limits of serum parameters. Black squares show ORs in quartiles (Q1–Q4), and the horizontal lines show 95% CIs. ORs are presented on a log scale. Chi-square test was used for determination of linear trends (\( P_{\text{trend}} \)) among the groups classified by tumor receptor status. HER2 human epidermal growth factor receptor 2, E1 estrone, E1S estrone sulfate, E2 estradiol, TE testosterone, AD androstenedione, SHBG sex hormone binding globulin, BMI body mass index, OR odds ratio, CI confidence interval. Statistics: *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \).
(OATP2B1) is responsible for the uptake of E1S in the cell (Ugele et al. 2003). OATP2B1 protein is strongly expressed in the epithelial cells in invasive ductal carcinomas of the breast. Its expression level correlated with the grade and stage of the disease (Al Sarakbi et al. 2006). Several studies reported that the expression of STS in tumor cells might imply the progression of the tumor and indicate a poor clinical outcome (Evans et al. 1994; Utsumi et al. 1999; Miyoshi et al. 2003b; Suzuki et al. 2009). In addition, increased STS expression has also been associated with clinical resistance to endocrine therapies (Chanplakorn et al. 2010) and higher histological grades (Al Sarakbi et al. 2006; Geisler et al. 2011).

Interestingly in triple receptor-positive cases (HER2+/ER+/PR+) the elevated steroid hormone concentrations and the significantly increased E1S/E1 ratio compared with HER2−/ER+/PR+ or triple-negative cases were associated with HR-positivity and HER2-positivity, respectively. This phenomenon might be due to molecular cross-talk between ER and the HER2 pathways (Dowsett et al. 2008; Tripathy et al. 2013; Mehta and Tripathy 2014). Several studies indicated that the estrogen-mediated activation of G-protein coupled ER1 (GPER1) was associated with several rapid cellular signaling events including activation of epidermal growth factor receptor (EGFR) (Filardo et al. 2006; Ignatov et al. 2010; Ignatov et al. 2011; Jiang et al. 2013). According to De Franceso et al. (2014) estrogenic GPER signaling is able to trigger hypoxia-inducible factor 1A (HIF1A)-dependent vascular endothelial growth factor (VEGF) expression that supports angiogenesis and progression in breast cancer (De Francesco et al. 2014).

Another possible explanation is that estrogens promote the growth, stromalization and angiogenesis of an ER-negative breast cancer cell line (Gupta and Kupperwasser 2006; Gupta et al. 2007). These studies suggest that E2 can act as a potent metastasis-promoter in ER-negative tumors by a novel mechanism involving the host microenvironment.

Best to our knowledge we are the first who demonstrated that elevated E1S concentration and E1S/E1 ratio may be linked with HER2-positive tumors and possibly may indicate an impact of STS pathway. Because of the small number of HER2+/ER+/PR+ cases further investigations are needed to verify this hypothesis.

Our findings that serum E1 level and BMI are significantly elevated in PR+ and ER+/PR+ cases is in line with literary data and supports the role of aromatase route (Cauley et al. 1989). In HER2+ cases a decreased E1 level is associated with a significantly decreased BMI. In postmenopausal breast cancer patients obesity-associated higher estrogen levels might be explain with that aromatization is the major source of estrogens in contrast to an ovarian source in premenopausal women. An increasing volume of adipose tissue in obesity is associated with an increase in total body aromatase activity (Goodwin 2013). The surrounding adipose tissue has an influence to the steroid biosynthesis in the tumor itself. Our hypothesis is that instead of aromatase, STS pathway will be preferred in HER2+ cases.

These results raise the notion that macro-environmental concentrations and conversion of conjugated-unconjugated E1 in peripheral tissue and aromatization of AD and TE to E1 and E2 in adipose tissue might influence the micro-environmental (normal breast) and intrinsic (breast tumor) biosynthesis of estrogens. Our result draws attention to the importance of STS pathways. Measurement of serum E1 and E1S concentrations, and their ratio, and the assessment of tumor receptor status might support the selection of the appropriate therapy, and the individualization of regime.

Therefore, the measurement of serum estrone and estrone sulfate concentrations prior to surgical intervention in postmenopausal primary breast cancer patients might be of benefit.

Abbreviations
AD: androstenedione; BMI: body mass index; CI: confidence interval; DHEA: dehydroepiandrosterone; DHEAS: dehydroepiandrosterone sulfate; E2: estradiol; ER: estrogen receptor; E1: estrone; E1S: estrone sulfate; FISH: fluorescence in situ hybridization; GPER1: G-protein coupled ER1; HRT: hormone replacement therapy; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; HIF1A: hypoxia-inducible factor 1A; IHC: immunohistochemical; IDC: invasive ductal carcinoma; DGC: invasive ductal carcinoma in situ; IL: invasive lobular carcinoma; OATP2B1: organic anion transport protein 2B1; OR: odds ratio; PR: progesterone receptor; SHBG: sex hormone binding globulin; STS: steroid sulfatase; TE: testosterone; VEGF: vascular endothelial growth factor.

Authors’ contributions
BV conception and design, project development, analysis and interpretation of data, manuscript writing. BK analysis and interpretation of data, performed the statistical analysis, figure editing, NU hishtochemical, genetical determination of steroid receptors and HER2. Consultations concerning to molecular markers of breast carcinomas (phenotype, genotyype); ZH participant as a physician, consultations concerning to treatment modalities and clinical impacts, ZM participant as a physician, project development, responsible for selection of patients (blood taken) and clinical impacts, FCP participant as a physician, responsible for selection of patients (blood taken), KK acquisition of data, project development, drafting and editing manuscript; JK design of experiments, evaluation of the results, acquisition of data, MB evaluation of the results, editing manuscript; IL participant as a physician, consultations concerning to treatment modalities and clinical impacts, revising manuscript critically for important intellectual content, has given final approval of the version to be published; MK project development. All authors read and approved the final manuscript.

Author details
1 Department of Biochemistry, National Institute of Oncology, 1122 Budapest, Ráth György u. 7-9., Hungary. 2 Surgical and Molecular Tumor Pathology Centre, National Institute of Oncology, Budapest, Hungary. 3 Clinic of Oncology, Centre of Clinics, University of Debrecen, 4032 Debrecen, Nagyerdéki krt. 98., Hungary. 4 Department of General and Thoracic Surgery, National Institute of Oncology, Budapest, Hungary. 5 Medical Oncology and Clinical Pharmacology “B”, National Institute of Oncology, Budapest, Hungary. 6 National Institute of Oncology, Budapest, Hungary.
Acknowledgements
The authors thank to Beatrix Susztrik for support the experiments and her excellent technical assistance. The authors are grateful to the staff members of the Biochemical, General and Thoracic Surgery, Medical Oncology and Clinical Pharmacology “B” Departments, and Surgical and Molecular Tumor Pathology Centre of National Institute of Oncology, Hungary. The authors also thank for the Budalabor Ltd. (Hungary) to MedCalc® v.12.1.3. statistical software.

Compliance with ethical guidelines

Competing interests
The authors declare that they have no competing interests.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not for profit sector.

Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Received: 20 July 2015   Accepted: 20 July 2015

Published online: 31 July 2015

References

Al Sarakbi W, Mokbel R, Salhab M, Jiang WG, Reed MJ, Mokbel K (2006) The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res 26:4985–4990

Ayisla K, Desai A, Welch C, Xu J, Qin Y, Reddy V et al (2013) Triple negative breast cancer – an overview. Hered Genet 2013(Suppl 2), doi:10.4172/2161-1041.S2-001

Begg CB, Zhang ZF (1994) Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomark Prev 3:173–177

Borner J, Walker J, Purohit A, Reed MJ, Potter BVL, Willis DS et al (2000) Human granulosa cells are a site of sulphatase activity and are able to utilize dehydroepiandrosterone sulphate as a precursor for oestradiol production. J Endocrinol 167:465–471

Cauley JA, Gural JR, Kuller LH, LeDonne DJ, Powell JG (1989) The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 129:120–131

Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y et al (2010) Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 120:639–648

Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauleys JA (2005) Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomark Prev 14:1047–1051

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98

De Francesco EM, Pellegrino M, Santolla MF, Lappano R, Ricchio E, Abonante S et al (2014) GPR30 mediates activation of HIF1α signaling by androgens. Cancer Res 74:4053–4064

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wake C et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epithelial growth factor receptor 2 (HER-2) status with recurrence in the Antrixmed, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065

Endogenous hormones and Breast Cancer Collaborative Group (2003) Free estradiol and breast cancer risk in postmenopausal women: comparison of measured and calculated values. Cancer Epidemiol Biomark Prev 12:1457–1461

Endogenous Hormones and Breast Cancer Collaborative Group (2013) Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 14:1009–1019

Evans TR, Rowlands MG, Law M, Coombes RC (1994) Intratumoral oestrione sulphatase activity as a prognostic marker in human breast carcinoma. Br J Cancer 69:555–561

Falany JL, Falany CN (2007) Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. J Steroid Biochem Mol Biol 107:202–210

Fiallo EI, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA et al (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12:6359–6366

Garriott A, Munoz Y, Sierralta W, Valladares L (2012) Metabolism of dehydroepiandrosterone sulfate and estrone-sulfate by human platelets. Physiol Rev 61:381–388

Geisler J, Sasano H, Chen S, Purohit A (2011) Steroid sulfatase inhibitors: promising new tools for breast cancer therapy? J Steroid Biochem Mol Biol 125:39–45

Goodwin PJ (2013) Obesity and endocrine therapy: host factors and breast cancer. Breast 22:544–547

Gupta PB, Kuperwasser C (2006) Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 102:71–78

Gupta PB, Proia D, Cingoz O, Weremowicz S, Naber SP, Weinberg RA et al (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67:2062–2071

Hankinson SE, Eliassen AH (2007) Endogenous estrogen, testosterone and progesterone levels in relation to breast cancer risk. J Steroid Biochem Mol Biol 106:24–30

Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123:87–96

Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A et al (2011) G-protein coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128:457–466

Jiang QF, Wu TT, Yang JY, Dong CR, Wang N, Liu XH et al (2013) 17β-Estradiol promotes the invasion and migration of nuclear estrogen receptor-negative breast cancer cells through cross-talk between GPER1 and CXXCR1. J Steroid Biochem Mol Biol 138:314–324

Kaako R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071–1082

Key T, Appleby P, Barnes I, Reeves G, Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616

Kim JY, Han W, Moon HG, Ahn SK, Kim J, Lee JW et al (2013) Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer 13:503–508

Labrie F (2015) All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J Steroid Biochem Mol Biol 145:133–138

Läng I, Zu Kahún, Hitre E, Dank M, Rubovszky G, Horváth Z et al (2012) Modern pharmacological therapy of breast cancer. Endocr Rev 35:56–65

Mehta A, Tripathy D (2014) Co-targeting estrogen receptor and HER2 pathways in breast cancer. The breast 23:2–9

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856–1865

Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2003b) Association of serum estradiol and breast cancer risk in postmenopausal Japanese women. Clin Cancer Res 9:2229–2233

Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S (2003b) Association of serum estradiol and breast cancer risk in postmenopausal Japanese women. Clin Cancer Res 9:2229–2233
Perou CM (2011) Molecular stratification of triple-negative breast cancers. Oncologist 16:61–70
Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368
Russo J, Russo IH (2006) The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 102:89–96
Sieri S, Krogh V, Boyle L, Abagnato CA, Grioni S, Pala V et al (2009) Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomark Prev 18:169–176
Suzuki M, Ishida H, Shiotsu Y, Nakata T, Akinaga S, Takashima S et al (2009) Expression level of enzymes related to in situ estrogen synthesis and clinico-pathological parameters in breast cancer patients. J Steroid Biochem Mol Biol 113:195–201
Tripathy D, Kaufman PA, Brufsky AM, Mayer M, Yood MU, Yoo B et al (2013) First line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER. Oncologist 18:501–510
Ugele B, St-Pierre MV, Pihusch M, Bahn A, Hantschmann P (2003) Characterization and identification of steroid sulfate transporters of human placenta. Am J Physiol Endocrinol Metab 284:E390–E398
Utsumi T, Yoshimura N, Takeuchi S, Andro J, Maruta M, Maeda K et al (1999) Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res 59:377–381
Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672
Wurtz AM, Tjanneland A, Christensen J, Dragsted LO, Aarestrup J, Kyra C et al (2012) Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy. Cancer Causes Control 23:1711–1720
Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I et al (2004) Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90:153–159
Zhang X, Tworoger SS, Eliassen AH, Hankinson SE (2013) Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat 137:883–892